Back to the full story5 sources · Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial◆ Analytics
Personalized mRNA cancer vaccine shows promise in extending life span in melanoma trial
Deterministic text analytics computed across all 5 sources. Frequency, entity overlap, and claim overlap — computed counts only. Nothing is rated true or false.
01
Frequency Analytics
The most common words and exact phrases across every report in this cluster. Computed counts only.
Top words
melanomavaccinecancertrialpersonalizedmerckstagemrnalatepatients
Top phrases
cancer vaccinelate stagepersonalized mrnacancer vaccine succeededmrna cancer vaccinevaccine succeededlate stage trialvaccine showsmrna cancerstage trial
02
Entity Overlap
Names detected in the report text: which appear across multiple sources, and which only one source mentions.
Across multiple sources
- Merck · 4 sources
- Moderna · 4 sources
- Keytruda · 3 sources
- Phase · 2 sources
Unique to one source
- Experimental · CBS News — Top
- It's · CBS News — Top
- Jon LaPook · CBS News — Top
- Personalized · ABC7 Los Angeles
- Cancer · CNBC
- Moderna’s · Fortune
- Merck’s · Fortune
- Merck's Keytruda · Fortune
- STAT · STAT
- Continue · STAT
03
Claim Overlap
Near-identical sentences found in two or more reports, versus sentences that appear in only one. Text match only — nothing is rated true or false.
Repeated across sources
No sentence appeared in more than one source.
Appears once
- "An experimental melanoma vaccine could reduce the risk of the cancer returning or spreading for some high-risk patients." · CBS News — Top
- "It's personalized for each patient and optimized using artificial intelligence." · CBS News — Top
- "Merck and Moderna announced Wednesday that a personalized mRNA-based cancer vaccine succeeded in a large, late-stage trial among high-risk patients with melanoma." · ABC7 Los Angeles
- "The combination regimen significantly extended the time patients lived without their melanoma returning, compared with Keytruda alone." · CNBC
- "The shot, paired with Merck's Keytruda, cut the risk of melanoma recurrence in a trial of more than 1,100 patients." · Fortune
- "Moderna and Merck said Wednesday their personalized mRNA cancer vaccine met its main goals in a Phase 3 trial targeting melanoma, marking the first time a therapy of its kind has succeeded at that stage of testing." · Fortune
- "A personalized mRNA cancer vaccine succeeded in a late-stage melanoma study, results that could herald a new, powerful approach in oncology." · STAT
- "A personalized mRNA cancer vaccine, added to an existing treatment, slowed the return of melanoma and its spread to other parts of the body in a late-stage clinical trial, the drugmakers Merck and Moderna announced Wednesday, results that could herald a new, powerful approach in oncology." · STAT